PPP2CB通过LOX-1/MAPK/ERK信号通路加剧动脉样硬化相关的脂质失调症
He An1, Dong-Liang Cheng2, Xian-Ru Xia1
1Department of Laboratory Medicine, Taihe Hospital, Hubei University of Medicine, Hubei, Shiyan, China.
Lipids in health and disease
|July 3, 2025
概括
蛋白酸酶2催化子单元β (PPP2CB) 是动脉样硬化 (AS) 中的一种新型脂质调节剂. PPP2CB的升调会加剧脂质积累,并通过LOX-1/MAPK/ERK通路促进AS的进展.
科学领域:
- 心血管生物学 心血管生物学
- 分子医学是分子医学.
- 脂质代谢 脂质代谢是什么
背景情况:
- 脱脂症是心血管疾病和动脉样硬化 (AS) 的主要驱动因素.
- 向脂质稳态提供了AS的治疗潜力.
- 蛋白酸酶2催化子单元β (PPP2CB) 在AS相关的脂质失调症中的作用尚不清楚.
研究的目的:
- 调查PPP2CB在AS和失脂症病变的发病过程中的作用.
- 阐明PPP2CB在脂质代谢中的功能背后的分子机制.
主要方法:
- 在人类AS患者和动物模型中分析PPP2CB表达.
- 在体外研究中,使用暴露于高脂刺激的肝细胞.
- 分子技术包括西部抹杀,qRT-PCR,共免疫沉和LDL-C吸收测试.
- 对大动脉动脉硬化病变和信号通路激活的评估.
主要成果:
- 在AS患者,高脂血症小鼠和肝细胞中,PPP2CB显著上调.
- 过度表达PPP2CB恶化了肝细胞中的脂质积累和LDL-C吸收.
- PPP2CB直接与LOX-1相互作用,调节其表达并激活LOX-1/MAPK/ERK通路.
结论:
- 在AS进展中,PPP2CB充当脂质代谢的新型调节者.
- 在异常的脂质代谢过程中,PPP2CB与信号通路调节有关.
- PPP2CB为AS提供了一个潜在的治疗标和生物标志物.
更多相关视频
11:00A Model of Disturbed Flow-Induced Atherosclerosis in Mouse Carotid Artery by Partial Ligation and a Simple Method of RNA Isolation from Carotid Endothelium
Published on: June 22, 2010
28.9K
03:42Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
Published on: March 29, 2024
1.7K
相关概念视频
Atherosclerosis I: Introduction
92
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
92
Atherosclerosis III: Management
41
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
41
Coronary Artery Disease II: Pathophysiology
40
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
40
Peripheral Artery Disease I: Introduction
35
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
35
Inflammation
55.3K
Overview
55.3K
Coronary Artery Disease I: Introduction
63
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
63
